<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id><journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id><journal-title-group><journal-title>BMC Research Notes</journal-title></journal-title-group><issn pub-type="epub">1756-0500</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31924263</article-id><article-id pub-id-type="pmc">6954502</article-id><article-id pub-id-type="publisher-id">4891</article-id><article-id pub-id-type="doi">10.1186/s13104-020-4891-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Note</subject></subj-group></article-categories><title-group><article-title>Association of rs780094 polymorphism of glucokinase regulatory protein with non-alcoholic fatty liver disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mohammadi</surname><given-names>Saba</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6087-9147</contrib-id><name><surname>Farajnia</surname><given-names>Safar</given-names></name><address><email>farajnias@tbzmed.ac.ir</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shadmand</surname><given-names>Masoud</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mohseni</surname><given-names>Fatemeh</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Baghban</surname><given-names>Roghayyeh</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2174 8913</institution-id><institution-id institution-id-type="GRID">grid.412888.f</institution-id><institution>Drug Applied Research Center, </institution><institution>Tabriz University of Medical Sciences, </institution></institution-wrap>Tabriz, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2174 8913</institution-id><institution-id institution-id-type="GRID">grid.412888.f</institution-id><institution>Biotechnology Research Center, </institution><institution>Tabriz University of Medical Sciences, </institution></institution-wrap>Tabriz, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2174 8913</institution-id><institution-id institution-id-type="GRID">grid.412888.f</institution-id><institution>Nutrition Research Center, Department of Community Nutrition, School of Nutrition, </institution><institution>Tabriz University of Medical Sciences, </institution></institution-wrap>Tabriz, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2174 8913</institution-id><institution-id institution-id-type="GRID">grid.412888.f</institution-id><institution>Immunology Research Center, </institution><institution>Tabriz University of Medical Sciences, </institution></institution-wrap>Tabriz, Iran </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>13</volume><elocation-id>26</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>3</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objective</title><p id="Par1">GCK rs780094 polymorphism is a single nucleotide polymorphism that has been associated with obesity, type II diabetes and dyslipidemia in some populations, conditions that highly related to NAFL etiology. The present study aimed to evaluate the relationship between NAFLD and rs780094 polymorphism in patients with NAFLD in Tabriz city, northwest of Iran. The rs780094 polymorphism was determined in 74 patients with NAFLD by PCR&#x02013;RFLP technique. Demographic information was collected using a questionnaire and biochemical analysis was performed using standard laboratory methods.</p></sec><sec><title>Results</title><p id="Par2">There was a significant difference between case and control subjects for alanine aminotransferase, aspartate aminotransferase, HDL-C and triglycerides (<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05). Analysis by PCR&#x02013;RFLP method revealed that there were no significant differences between NAFLD and healthy subjects for rs780094 polymorphism in the study population. The results of this study indicated that rs780094 polymorphism is not associated with NAFLD in subjects from Tabriz city.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>NAFLD</kwd><kwd>rs780094 polymorphism</kwd><kwd>Biochemical parameters</kwd><kwd>Demographic parameters</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002958</institution-id><institution>Drug Applied Research Center, Tabriz University of Medical Sciences</institution></institution-wrap></funding-source><award-id>64244</award-id><principal-award-recipient><name><surname>Farajnia</surname><given-names>Safar</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par15">Non-alcoholic fatty liver disease (NAFLD), was first identified in 1980 by Ludwig et al., through fatty infiltration of the liver among non-alcoholic patients [<xref ref-type="bibr" rid="CR1">1</xref>]. NAFLD is considered as a major public health concern due to increasing prevalence of obesity in both children and adults. The disease is diagnosed by hepatic steatosis or presence of fat in liver parenchyma without inflammation and also in the absence of excessive alcohol consumption. NAFLD is also known as a hepatic component of metabolic syndrome [<xref ref-type="bibr" rid="CR2">2</xref>] which includes a broad range of clinic pathological conditions ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) [<xref ref-type="bibr" rid="CR3">3</xref>]. The progressed NASH is identified through cellular necrosis and inflammatory infiltration that can subsequently create complications such as cirrhosis, liver failure and hepatocellular carcinoma [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par16">Genetic variants, as likely etiological factors, are investigated for NAFLD due to its familial clustering [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Some research studies have shown a strong correlation between usual missense variant (rs738409) in the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene and susceptibility to NAFLD and NASH [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par17">Glucose-phosphorylating enzyme glucokinase is responsible for hepatic glucose metabolism and activation of hepatic lipogenesis. The expression of Glucokinase is regulated by GCKR [<xref ref-type="bibr" rid="CR10">10</xref>]. It has shown that GCKR, encoded by GCKR gene, allosterically binds to GCK and regulates its activity. Genome-wide association studies (GWAS) have recognized a single-nucleotide polymorphisms (SNPs) which increases the risk of NAFLD. It has shown that rs780094 polymorphism of GCKR is related to triglyceride levels [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Also, an association between rs780094 polymorphism of GCKR and diabetes, particularly in Asian population has reported in a previous study [<xref ref-type="bibr" rid="CR13">13</xref>]. Moreover, population studies showed that NAFLD is severely related to obesity, insulin resistance/type II diabetes mellitus and dyslipidemia [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Thus, we hypothesized the presence of a possible relationship between NAFLD and rs780094 polymorphism. The presence of a strong association between NAFLD, with diabetes mellitus and hepatic triglyceride accumulation and also an association between rs780094 polymorphism with diabetes and triglyceride levels supported our hypothesis. The present study investigated the relationship between NAFLD and rs780094 polymorphism in patients with NAFLD in subjects from Tabriz city in the north-west of Iran.</p></sec><sec id="Sec2"><title>Main text</title><sec id="Sec3"><title>Materials and methods</title><sec id="Sec4"><title>Subjects and samples</title><p id="Par18">This case&#x02013;control study was conducted on 74 patients with NAFLD that were confirmed by both sonography and high levels of liver enzymes. Also, 72 subjects without NAFLD were considered as control. The patients were randomly selected from patients in Gastrointestinal clinics. The subjects were informed about the purpose of the study and written informed consent was obtained. The inclusion criteria were similar in the case and control subjects, as follows; mean age 20&#x02013;50&#x000a0;years and mean body mass index (BMI) 25&#x02013;39.9&#x000a0;kg/m<sup>2</sup>. The exclusion criteria were also as follows; age ranging &#x0003e;&#x02009;50&#x000a0;years and &#x0003c;&#x02009;20&#x000a0;years, BMI &#x0003c;&#x02009;25&#x000a0;kg/m<sup>2</sup>, having hemochromatosis, Wilson and autoimmune diseases, tobacco and alcohol consumption, the use of hepatotoxic and psychotic drugs, weight loss diets over last 3&#x000a0;months, gland disorders, pregnancy and lactation, intestinal bypass surgery, acute and chronic liver diseases and viral hepatitis.</p></sec><sec id="Sec5"><title>Samples preparation and biochemical analysis</title><p id="Par19">Blood samples were collected from case and control subjects and transferred to molecular biology laboratory of biotechnology research center. The biochemical parameters consisting of alanine aminotransferase (ALT), aspartate aminotransferase (AST), low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and plasma triglyceride level was analyzed using standard laboratory techniques.</p></sec><sec id="Sec6"><title>Collection of anthropometric data</title><p id="Par20">The information related to age, sex, drug consumption, cigarette smoking, etc. were collected by questionnaire. BMI was defined as weight/height<sup>2</sup> (kg/m<sup>2</sup>). Waist and hip circumference and waist-to-hip ratio were also measured.</p></sec><sec id="Sec7"><title>DNA extraction and genotyping</title><p id="Par21">DNA was extracted from blood samples using salting-out method. Briefly, 500&#x000a0;&#x000b5;l of blood samples were transferred to the 15&#x000a0;ml tubes and the red blood cells were lysed by washing three times with lysis buffer (155&#x000a0;mm NH<sub>4</sub>Cl, 10&#x000a0;mM KHCO<sub>3</sub>, 10&#x000a0;mM EDTA). Then, 500&#x000a0;&#x000b5;l of DNG-Plus reagents (Cinnagen co, Iran) was added to the cell pellet and slowly stirred to obtain the homogenized sample. DNA was then precipitated by 350&#x000a0;&#x000b5;l of isopropanol, washed with ethanol 75% and dissolved in 50&#x000a0;&#x000b5;l distilled water. The extracted DNA was analyzed using electrophoresis on 1% agarose gel and spectrophotometry.</p><p id="Par22">RFLP-PCR was used to determinate the genotypes of subjects for rs738409 polymorphism. The DNA extracted from subjects was amplified with the following primers, Forward: 5&#x02032;-AGCTCACGCTGGAACTTCTG-3&#x02032; and Reverse: 5&#x02032;-CATGTTGGCTAGGCTTGTTGAG-3&#x02032;, using Taq DNA polymerase. PCR was performed in a final volume of 25&#x000a0;&#x000b5;l including; 10&#x000a0;pm of each primer, 100&#x000a0;ng of genomic DNA, 1&#x000a0;U of Taq DNA polymerase and 22&#x000a0;&#x000b5;l of PCR master mix. The PCR program for DNA amplification was as follows; initial denaturation at 94&#x000a0;&#x000b0;C for 4&#x000a0;min, 35 cycles of denaturation at 94&#x000a0;&#x000b0;C for 1&#x000a0;min, annealing at 53&#x000a0;&#x000b0;C for 1&#x000a0;min, extension at 72&#x000a0;&#x000b0;C for 45&#x000a0;s and final extension at 72&#x000a0;&#x000b0;C for 5&#x000a0;min. After PCR, 10&#x000a0;&#x000b5;l of PCR products were digested with 1&#x000a0;U of PscI enzyme for 1&#x000a0;h at 37&#x000a0;&#x000b0;C and visualized on 2% agarose gel, after staining with safestain. The 100-bp DNA ladder was used for determining the size of digested product. After electrophoresis, genotypes GG at 311&#x000a0;bp, CC at 194&#x000a0;bp and 117&#x000a0;bp and CG at 311 and 194&#x000a0;bp were detected.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par23">Statistical analysis was performed using SPSS software (Statistical Package for the Social Sciences) Version 23. Qualitative and quantitative data were expressed as Mean (&#x000b1;&#x02009;standard deviation) and frequency (%), respectively. The Mann&#x02013;Whitney U test and independent t-test were used for analysis of the data. <italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05 was considered significant.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Demographic and clinical characteristics</title><p id="Par24">Demographic and clinical data of the subjects have been demonstrated in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. There were significant differences between control and case group for HDL-C, triglycerides, ALT and AST (<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05), so that patients with NAFLD showed higher concentrations of triglycerides, ALT and AST and lower concentration of HDL-C compared to control group (<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Demographic and clinical data of the subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">Control (N&#x02009;=&#x02009;72)</th><th align="left">Case (N&#x02009;=&#x02009;74)</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Sex (men %)</td><td align="left">36.1</td><td align="left">48.6</td><td align="left">ns</td></tr><tr><td align="left">Sex (women %)</td><td align="left">63.9</td><td align="left">51.4</td><td align="left">ns</td></tr><tr><td align="left">Age (years)</td><td align="left">38.88&#x02009;&#x000b1;&#x02009;8.25</td><td align="left">40.54&#x02009;&#x000b1;&#x02009;8.42</td><td align="left">ns</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="left">31.51&#x02009;&#x000b1;&#x02009;4.09</td><td align="left">31.90&#x02009;&#x000b1;&#x02009;4.18</td><td align="left">ns</td></tr><tr><td align="left">Waist circumference (cm)</td><td align="left">100.2&#x02009;&#x000b1;&#x02009;8.75</td><td align="left">103.36&#x02009;&#x000b1;&#x02009;9.31</td><td align="left">ns</td></tr><tr><td align="left">Hip circumference (cm)</td><td align="left">111.86&#x02009;&#x000b1;&#x02009;8.05</td><td align="left">112.16&#x02009;&#x000b1;&#x02009;8.13</td><td align="left">ns</td></tr><tr><td align="left">Waist-to-hip ratio</td><td align="left">0.897&#x02009;&#x000b1;&#x02009;0.065</td><td align="left">0.922&#x02009;&#x000b1;&#x02009;0.052</td><td align="left">ns</td></tr><tr><td align="left">Weight (kg)</td><td align="left">84.66&#x02009;&#x000b1;&#x02009;12.15</td><td align="left">86.44&#x02009;&#x000b1;&#x02009;11.14</td><td align="left">ns</td></tr><tr><td align="left">Height (cm)</td><td align="left">164.04&#x02009;&#x000b1;&#x02009;10.19</td><td align="left">164.96&#x02009;&#x000b1;&#x02009;10.49</td><td align="left">ns</td></tr><tr><td align="left">Cholesterol (mg/dl)</td><td align="left">187.40&#x02009;&#x000b1;&#x02009;29.33</td><td align="left">183.08&#x02009;&#x000b1;&#x02009;37.03</td><td align="left">ns</td></tr><tr><td align="left">Triglycerides (mg/dl)</td><td align="left">140.71&#x02009;&#x000b1;&#x02009;75.84</td><td align="left">173.55&#x02009;&#x000b1;&#x02009;76.33</td><td align="left">*</td></tr><tr><td align="left">HDL-C (mg/dl)</td><td align="left">48.08&#x02009;&#x000b1;&#x02009;11.78</td><td align="left">43.09&#x02009;&#x000b1;&#x02009;11.43</td><td align="left">*</td></tr><tr><td align="left">LDL-C (mg/dl)</td><td align="left">110.98&#x02009;&#x000b1;&#x02009;26.64</td><td align="left">105.03&#x02009;&#x000b1;&#x02009;34.75</td><td align="left">ns</td></tr><tr><td align="left">ALT (IU/l)</td><td align="left">26.29&#x02009;&#x000b1;&#x02009;9.41</td><td align="left">49.99&#x02009;&#x000b1;&#x02009;26.16</td><td align="left">*</td></tr><tr><td align="left">AST (IU/l)</td><td align="left">22.97&#x02009;&#x000b1;&#x02009;6.11</td><td align="left">32.99&#x02009;&#x000b1;&#x02009;14.97</td><td align="left">*</td></tr><tr><td align="left">Fasting glucose (mg/dl)</td><td align="left">90.17&#x02009;&#x000b1;&#x02009;10.16</td><td align="left">90.47&#x02009;&#x000b1;&#x02009;11.27</td><td align="left">ns</td></tr></tbody></table><table-wrap-foot><p>*<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05; <italic>ns</italic> non-significant or <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Genotypic and allelic frequency of rs780094 polymorphism of GCKR</title><p id="Par25">The distribution of the GCKR rs780094 genotype for the case and control groups has shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Analysis of the results indicated that there was no significant difference between case and control groups for CT and TT genotypes. However, compared to the normal healthy control subjects, the frequency of CC genotypes was significantly lower in NAFLD patients (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Genotypic and allelic frequency (%) of GCKR rs780094</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Control (N&#x02009;=&#x02009;72)</th><th align="left">Case (N&#x02009;=&#x02009;74)</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">CC genotype</td><td char="." align="char">31.9</td><td char="." align="char">18.9</td><td align="left">ns</td></tr><tr><td align="left">CT genotype</td><td char="." align="char">47.2</td><td char="." align="char">48.6</td><td align="left">ns</td></tr><tr><td align="left">TT genotype</td><td char="." align="char">20.8</td><td char="." align="char">32.4</td><td align="left">ns</td></tr><tr><td align="left">T allele</td><td char="." align="char">0.44</td><td char="." align="char">0.57</td><td align="left">ns</td></tr><tr><td align="left">C allele</td><td char="." align="char">0.56</td><td char="." align="char">0.43</td><td align="left">ns</td></tr></tbody></table><table-wrap-foot><p>*<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05; <italic>ns</italic> non-significant or <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>Relation of demographic and clinical characteristics with GCKR rs780094</title><p id="Par26">Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows a correlation between demographic and clinical characteristics of subjects and GCKR rs780094 genotype. Logistic regression showed that there was not any correlation between demographic and clinical characteristics and GCKR rs780094 genotype; indicating lack of significant role of GCKR rs780094 genotype in NAFLD in the study population.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Relation of demographic and clinical characteristics with GCKR rs780094 genotype in patients with NAFLD (N&#x02009;=&#x02009;74)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">CC</th><th align="left">CT</th><th align="left">TT</th><th align="left">&#x003b2; coefficient</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Sex (men %)</td><td align="left">64.3</td><td align="left">38.9</td><td align="left">50</td><td align="left">&#x02013;</td><td align="left">ns</td></tr><tr><td align="left">Sex (women %)</td><td align="left">35.7</td><td align="left">61.1</td><td align="left">50</td><td align="left">&#x02013;</td><td align="left">ns</td></tr><tr><td align="left">Age (years)</td><td align="left">40.43&#x02009;&#x000b1;&#x02009;8.67</td><td align="left">42.58&#x02009;&#x000b1;&#x02009;8.10</td><td align="left">38.29&#x02009;&#x000b1;&#x02009;8.53</td><td align="left">&#x02212;&#x02009;0.027</td><td align="left">ns</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="left">30.70&#x02009;&#x000b1;&#x02009;3.05</td><td align="left">31.30&#x02009;&#x000b1;&#x02009;4.19</td><td align="left">32.16&#x02009;&#x000b1;&#x02009;4.59</td><td align="left">0.057</td><td align="left">ns</td></tr><tr><td align="left">Waist circumference (cm)</td><td align="left">100.0&#x02009;&#x000b1;&#x02009;7.33</td><td align="left">106.0&#x02009;&#x000b1;&#x02009;10.91</td><td align="left">101.0&#x02009;&#x000b1;&#x02009;7.53</td><td align="left">&#x02212;&#x02009;0.033</td><td align="left">ns</td></tr><tr><td align="left">Hip circumference (cm)</td><td align="left">108.0&#x02009;&#x000b1;&#x02009;7.14</td><td align="left">115.0&#x02009;&#x000b1;&#x02009;8.36</td><td align="left">111.0&#x02009;&#x000b1;&#x02009;7.10</td><td align="left">0.011</td><td align="left">ns</td></tr><tr><td align="left">Weight (kg)</td><td align="left">82.44&#x02009;&#x000b1;&#x02009;9.56</td><td align="left">88.78&#x02009;&#x000b1;&#x02009;11.59</td><td align="left">88.78&#x02009;&#x000b1;&#x02009;11.59</td><td align="left">0.136</td><td align="left">ns</td></tr><tr><td align="left">Height (cm)</td><td align="left">167.43&#x02009;&#x000b1;&#x02009;8.93</td><td align="left">163.28&#x02009;&#x000b1;&#x02009;10.81</td><td align="left">165.0&#x02009;&#x000b1;&#x02009;10.50</td><td align="left">0.103</td><td align="left">ns</td></tr><tr><td align="left">Cholesterol (mg/dl)</td><td align="left">176.64&#x02009;&#x000b1;&#x02009;45.27</td><td align="left">185.14&#x02009;&#x000b1;&#x02009;35.06</td><td align="left">182.17&#x02009;&#x000b1;&#x02009;33.75</td><td align="left">&#x02212;&#x02009;0.037</td><td align="left">ns</td></tr><tr><td align="left">Triglycerides (mg/dl)</td><td align="left">184.71&#x02009;&#x000b1;&#x02009;68.55</td><td align="left">172.64&#x02009;&#x000b1;&#x02009;88.37</td><td align="left">187.08&#x02009;&#x000b1;&#x02009;39.37</td><td align="left">0.007</td><td align="left">ns</td></tr><tr><td align="left">HDL-C (mg/dl)</td><td align="left">43.00&#x02009;&#x000b1;&#x02009;10.94</td><td align="left">43.97&#x02009;&#x000b1;&#x02009;11.79</td><td align="left">43.08&#x02009;&#x000b1;&#x02009;11.07</td><td align="left">&#x02212;&#x02009;0.007</td><td align="left">ns</td></tr><tr><td align="left">LDL-C (mg/dl)</td><td align="left">96.70&#x02009;&#x000b1;&#x02009;40.81</td><td align="left">107.77&#x02009;&#x000b1;&#x02009;29.91</td><td align="left">101.67&#x02009;&#x000b1;&#x02009;35.29</td><td align="left">0.051</td><td align="left">ns</td></tr><tr><td align="left">ALT (IU/l)</td><td align="left">52.21&#x02009;&#x000b1;&#x02009;20.25</td><td align="left">44.11&#x02009;&#x000b1;&#x02009;29.10</td><td align="left">56.75&#x02009;&#x000b1;&#x02009;23.80</td><td align="left">0.012</td><td align="left">ns</td></tr><tr><td align="left">AST (IU/l)</td><td align="left">36.29&#x02009;&#x000b1;&#x02009;10.97</td><td align="left">29.61&#x02009;&#x000b1;&#x02009;12.41</td><td align="left">36.67&#x02009;&#x000b1;&#x02009;19.04</td><td align="left">&#x02212;&#x02009;0.010</td><td align="left">ns</td></tr><tr><td align="left">Fasting glucose (mg/dl)</td><td align="left">90.57&#x02009;&#x000b1;&#x02009;8.57</td><td align="left">92.06&#x02009;&#x000b1;&#x02009;10.08</td><td align="left">88.00&#x02009;&#x000b1;&#x02009;13.32</td><td align="left">&#x02212;&#x02009;0.005</td><td align="left">ns</td></tr></tbody></table><table-wrap-foot><p><italic>ns</italic> non-significant or <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par27">Genome-wide association studies have shown that polymorphisms in the glucokinase regulatory protein are related to triglyceride level, obesity, insulin resistance/type II diabetes mellitus and dyslipidemia [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>], common conditions associated with NAFLD disorder. Therefore, we aimed to investigate the relationship between the GCKR rs780094 variant and NAFLD in patients in&#x000a0;the city of Tabriz, northwest of Iran.</p><p id="Par28">The results of the current study indicated that TT genotype had a higher frequency in NAFLD cases compared to the control group, although this difference was not significant (<italic>P&#x02009;</italic>&#x0003e;&#x02009;0.05). This finding was against a report from china. Yang et al. in 2011. [<xref ref-type="bibr" rid="CR11">11</xref>] reported that the GCKR variants could be considered as a risk factor for NAFLD; however their control study group was not obese.</p><p id="Par29">A meta-analysis has also shown that GCKR rs780094 T allele is a protective factor against diabetes and obesity [<xref ref-type="bibr" rid="CR11">11</xref>]. Some other studies have shown a significant association between GCKR rs780094 and NAFLD [<xref ref-type="bibr" rid="CR18">18</xref>]. However, the lack of relationship between the GCKR rs780094 genotype and the NAFLD, in the present study, might be attributed to the different ethnic background of the studied groups. In the current study, there was no association between GCKR rs780094 and anthropometric characteristics of the patients. It has known that anthropometric parameters not only related to the genetic background but also dependent on lifestyle. In a study on Iranian population, it has been shown a relationship among NAFLD, age, gender, obesity, metabolic syndrome, triglycerides, higher glucose, blood pressure and waist circumference [<xref ref-type="bibr" rid="CR19">19</xref>]. Bhatt et al. [<xref ref-type="bibr" rid="CR20">20</xref>] reported lack of any significant correlation between age and NAFLD in Asian Indians. Consistent with our findings, Lin et al. [<xref ref-type="bibr" rid="CR21">21</xref>] in a study on Taiwanese children reported lack of significant association between NAFLD, age, BMI and waist circumference.</p><p id="Par30">ALT and AST are known as liver biomarkers and liver injuries in NAFLD can disturb ALT and AST levels. Moreover, liver is known as a metabolizing organ for lipids, thus NAFLD, as a liver disorder, can disturb lipid levels. Our results indicated significant changes in HDL-C, triglycerides, AST and ALT as risk factors. In agreement with our results, Bhatt et al. [<xref ref-type="bibr" rid="CR20">20</xref>] and Hotta et al. [<xref ref-type="bibr" rid="CR22">22</xref>] reported that ALT and AST were significantly higher in NAFLD group compared to healthy controls in Asian populations.</p><p id="Par31">In contrast to our findings, Petta et al. [<xref ref-type="bibr" rid="CR23">23</xref>] reported that HDL, triglycerides, cholesterol and ALT did not show significant difference between case and control groups. In another investigation, Shen et al. [<xref ref-type="bibr" rid="CR24">24</xref>] could not find significant difference for fasting glucose, cholesterol and triglycerides.</p><p id="Par32">These discrepancies in findings of different studies might be attributed to the variations in the stage of disease, sample size and different ethnic background.</p></sec><sec id="Sec14"><title>Conclusion</title><p id="Par33">The results of our study indicated that GCKR rs780094 TT genotype is not responsible for NAFLD in the studied population. Our results also showed that age, sex, BMI, cholesterol, fasting glucose, LDL-C, waist circumference, hip circumference and waist-to-hip ratio were not significantly different in case and control groups. Changes in triglycerides, ALT, AST, and HDL-C were found as risk factors of NAFLD in the study groups. Further studies with larger sample size could be helpful in holding more relevant findings and interventional designs are needed to determine the effects of dietary compounds in different GCKR genotypes in nonalcoholic fatty liver disease.</p></sec><sec id="Sec15"><title>Limitations</title><p id="Par34">In the present manuscript, we explored the association of rs780094 polymorphism in GCKR with NAFLD and couldn&#x02019;t find any association. Therefore, these results are specifically valid for the study population and its generalization to other population needs further studies.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>PCR</term><def><p id="Par3">polymerase chain reaction</p></def></def-item><def-item><term>RFLP</term><def><p id="Par4">fragment length polymorphism</p></def></def-item><def-item><term>NAFLD</term><def><p id="Par5">non-alcoholic fatty liver disease</p></def></def-item><def-item><term>PNPLA3</term><def><p id="Par6">phospholipase domain-containing protein 3</p></def></def-item><def-item><term>NASH</term><def><p id="Par7">non-alcoholic steatohepatitis</p></def></def-item><def-item><term>GCKR</term><def><p id="Par8">glucokinase regulatory</p></def></def-item><def-item><term>SNPs</term><def><p id="Par9">single-nucleotide polymorphisms</p></def></def-item><def-item><term>GWAS</term><def><p id="Par10">genome-wide association studies</p></def></def-item><def-item><term>ALT</term><def><p id="Par11">alanine aminotransferase</p></def></def-item><def-item><term>AST</term><def><p id="Par12">aspartate aminotransferase</p></def></def-item><def-item><term>LDL</term><def><p id="Par13">low density lipoprotein</p></def></def-item><def-item><term>HDL</term><def><p id="Par14">high density lipoprotein</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was supported by Drug Applied Research Center, Tabriz University of Medical Science. We thank our colleagues from Drug Applied Research Center who provided insight and expertise that greatly assisted the research.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>SM performed the experiments and wrote the first draft of the manuscript, SF designed and supervised the study, MS analyzed data and co-wrote the paper, FM involved in data collection and analysis and RB prepared the revised version of the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by a grant from Drug Applied Research Center (Grant No. 64244), Tabriz University of Medical Science, Tabriz, Iran. The funding body had no any role in the study design data collection, analysis or writing of the manuscript.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>All data generated or analysed during this study are included in this published article.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par35">The subjects were informed about the purpose of the study and written informed consent was obtained. The study was approved by the Ethics Committee of Tabriz University Of Medical Sciences (IR.TBZMED.REC.1398.95).</p></notes><notes><title>Consent for publication</title><p id="Par36">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par37">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>J</given-names></name><name><surname>Viggiano</surname><given-names>TR</given-names></name><name><surname>Mcgill</surname><given-names>DB</given-names></name><name><surname>Oh</surname><given-names>B</given-names></name></person-group><article-title>Nonalcoholic steatohepatitis Mayo Clinic experiences with a hitherto unnamed disease</article-title><source>Mayo Clinic Proc.</source><year>1980</year><volume>55</volume><issue>7</issue><fpage>434</fpage><lpage>438</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalasani</surname><given-names>N</given-names></name><name><surname>Younossi</surname><given-names>Z</given-names></name><name><surname>Lavine</surname><given-names>JE</given-names></name><name><surname>Diehl</surname><given-names>AM</given-names></name><name><surname>Brunt</surname><given-names>EM</given-names></name><name><surname>Cusi</surname><given-names>K</given-names></name><name><surname>Charlton</surname><given-names>M</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group><article-title>The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association</article-title><source>Hepatology</source><year>2012</year><volume>55</volume><issue>6</issue><fpage>2005</fpage><lpage>2023</lpage><pub-id pub-id-type="doi">10.1002/hep.25762</pub-id><pub-id pub-id-type="pmid">22488764</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andy</surname><given-names>SY</given-names></name><name><surname>Keeffe</surname><given-names>EB</given-names></name></person-group><article-title>Nonalcoholic fatty liver disease</article-title><source>Gastroenterol Disord.</source><year>2002</year><volume>2</volume><issue>1</issue><fpage>B11</fpage><lpage>B19</lpage></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ioannou</surname><given-names>GN</given-names></name><name><surname>Haigh</surname><given-names>WG</given-names></name><name><surname>Thorning</surname><given-names>D</given-names></name><name><surname>Savard</surname><given-names>C</given-names></name></person-group><article-title>Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis</article-title><source>J Lipid Res</source><year>2013</year><volume>54</volume><issue>5</issue><fpage>1326</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1194/jlr.M034876</pub-id><pub-id pub-id-type="pmid">23417738</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwimmer</surname><given-names>JB</given-names></name><name><surname>Celedon</surname><given-names>MA</given-names></name><name><surname>Lavine</surname><given-names>JE</given-names></name><name><surname>Salem</surname><given-names>R</given-names></name><name><surname>Campbell</surname><given-names>N</given-names></name><name><surname>Schork</surname><given-names>NJ</given-names></name><name><surname>Shiehmorteza</surname><given-names>M</given-names></name><name><surname>Yokoo</surname><given-names>T</given-names></name><name><surname>Chavez</surname><given-names>A</given-names></name><name><surname>Middleton</surname><given-names>MS</given-names></name></person-group><article-title>Heritability of nonalcoholic fatty liver disease</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><issue>5</issue><fpage>1585</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.01.050</pub-id><pub-id pub-id-type="pmid">19208353</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romeo</surname><given-names>S</given-names></name><name><surname>Kozlitina</surname><given-names>J</given-names></name><name><surname>Xing</surname><given-names>C</given-names></name><name><surname>Pertsemlidis</surname><given-names>A</given-names></name><name><surname>Cox</surname><given-names>D</given-names></name><name><surname>Pennacchio</surname><given-names>LA</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Cohen</surname><given-names>JC</given-names></name><name><surname>Hobbs</surname><given-names>HH</given-names></name></person-group><article-title>Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease</article-title><source>Nature Genet.</source><year>2008</year><volume>40</volume><issue>12</issue><fpage>1461</fpage><pub-id pub-id-type="doi">10.1038/ng.257</pub-id><pub-id pub-id-type="pmid">18820647</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalasani</surname><given-names>N</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Loomba</surname><given-names>R</given-names></name><name><surname>Goodarzi</surname><given-names>MO</given-names></name><name><surname>Haritunians</surname><given-names>T</given-names></name><name><surname>Kwon</surname><given-names>S</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Wilson</surname><given-names>L</given-names></name><name><surname>Cummings</surname><given-names>OW</given-names></name></person-group><article-title>Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease</article-title><source>Gastroenterology</source><year>2010</year><volume>139</volume><issue>5</issue><fpage>1567</fpage><lpage>1576</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.07.057</pub-id><pub-id pub-id-type="pmid">20708005</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speliotes</surname><given-names>EK</given-names></name><name><surname>Yerges-Armstrong</surname><given-names>LM</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Hernaez</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>LJ</given-names></name><name><surname>Palmer</surname><given-names>CD</given-names></name><name><surname>Gudnason</surname><given-names>V</given-names></name><name><surname>Eiriksdottir</surname><given-names>G</given-names></name><name><surname>Garcia</surname><given-names>ME</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name></person-group><article-title>Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits</article-title><source>PLoS Genet</source><year>2011</year><volume>7</volume><issue>3</issue><fpage>e1001324</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1001324</pub-id><pub-id pub-id-type="pmid">21423719</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zain</surname><given-names>SM</given-names></name><name><surname>Mohamed</surname><given-names>R</given-names></name><name><surname>Mahadeva</surname><given-names>S</given-names></name><name><surname>Cheah</surname><given-names>PL</given-names></name><name><surname>Rampal</surname><given-names>S</given-names></name><name><surname>Basu</surname><given-names>RC</given-names></name><name><surname>Mohamed</surname><given-names>Z</given-names></name></person-group><article-title>A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease</article-title><source>Hum Genet</source><year>2012</year><volume>131</volume><issue>7</issue><fpage>1145</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1007/s00439-012-1141-y</pub-id><pub-id pub-id-type="pmid">22258181</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>CK</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Pakstis</surname><given-names>AJ</given-names></name><name><surname>Kim</surname><given-names>G</given-names></name><name><surname>Kursawe</surname><given-names>R</given-names></name><name><surname>Dykas</surname><given-names>DJ</given-names></name><name><surname>Bale</surname><given-names>AE</given-names></name><name><surname>Giannini</surname><given-names>C</given-names></name><name><surname>Pierpont</surname><given-names>B</given-names></name></person-group><article-title>Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents</article-title><source>Hepatology</source><year>2012</year><volume>5</volume><issue>3</issue><fpage>781</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1002/hep.24806</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Ling</surname><given-names>C</given-names></name></person-group><article-title>Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people</article-title><source>Mol Biol Rep</source><year>2011</year><volume>38</volume><issue>2</issue><fpage>1145</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1007/s11033-010-0212-1</pub-id><pub-id pub-id-type="pmid">20625834</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>M</given-names></name><name><surname>Kao</surname><given-names>WHL</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Hoogeveen</surname><given-names>RC</given-names></name><name><surname>Rasmussen-Torvik</surname><given-names>LJ</given-names></name><name><surname>Astor</surname><given-names>BC</given-names></name><name><surname>North</surname><given-names>KE</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>K&#x000f6;ttgen</surname><given-names>A</given-names></name></person-group><article-title>Association of rs780094 in GCKR with metabolic traits and incident diabetes and cardiovascular disease: the ARIC Study</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><issue>7</issue><fpage>e11690</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0011690</pub-id><pub-id pub-id-type="pmid">20661421</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>D</given-names></name><name><surname>Cong</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Lv</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>Z</given-names></name></person-group><article-title>Genetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: evidence based on 298, 468 subjects</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><issue>2</issue><fpage>e55727</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0055727</pub-id><pub-id pub-id-type="pmid">23441155</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group><article-title>AGA technical review on nonalcoholic fatty liver disease</article-title><source>Gastroenterology</source><year>2002</year><volume>123</volume><issue>5</issue><fpage>1705</fpage><lpage>1725</lpage><pub-id pub-id-type="doi">10.1053/gast.2002.36572</pub-id><pub-id pub-id-type="pmid">12404245</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchesini</surname><given-names>G</given-names></name><name><surname>Brizi</surname><given-names>M</given-names></name><name><surname>Morselli-Labate</surname><given-names>AM</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name><name><surname>Bugianesi</surname><given-names>E</given-names></name><name><surname>McCullough</surname><given-names>AJ</given-names></name><name><surname>Forlani</surname><given-names>G</given-names></name><name><surname>Melchionda</surname><given-names>N</given-names></name></person-group><article-title>Association of nonalcoholic fatty liver disease with insulin resistance</article-title><source>Am J Med</source><year>1999</year><volume>107</volume><issue>5</issue><fpage>450</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/s0002-9343(99)00271-5</pub-id><pub-id pub-id-type="pmid">10569299</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>EE</given-names></name><name><surname>Cooksley</surname><given-names>WGE</given-names></name><name><surname>Hanson</surname><given-names>R</given-names></name><name><surname>Searle</surname><given-names>J</given-names></name><name><surname>Halliday</surname><given-names>JW</given-names></name><name><surname>Powell</surname><given-names>W</given-names></name></person-group><article-title>The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years</article-title><source>Hepatology</source><year>1990</year><volume>11</volume><issue>1</issue><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1002/hep.1840110114</pub-id><pub-id pub-id-type="pmid">2295475</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawano</surname><given-names>Y</given-names></name><name><surname>Cohen</surname><given-names>DE</given-names></name></person-group><article-title>Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease</article-title><source>J Gastroenterol</source><year>2013</year><volume>48</volume><issue>4</issue><fpage>434</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1007/s00535-013-0758-5</pub-id><pub-id pub-id-type="pmid">23397118</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zain</surname><given-names>SM</given-names></name><name><surname>Mohamed</surname><given-names>Z</given-names></name><name><surname>Mohamed</surname><given-names>R</given-names></name></person-group><article-title>A common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis</article-title><source>J Gastroenterol Hepatol</source><year>2015</year><volume>30</volume><issue>1</issue><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1111/jgh.12714</pub-id><pub-id pub-id-type="pmid">25167786</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabir</surname><given-names>A</given-names></name><name><surname>Pourshams</surname><given-names>A</given-names></name><name><surname>Khoshnia</surname><given-names>M</given-names></name><name><surname>Malekzadeh</surname><given-names>F</given-names></name></person-group><article-title>Normal limit for serum alanine aminotransferase level and distribution of metabolic factors in old population of Kalaleh, Iran</article-title><source>Hepat Mon.</source><year>2013</year><pub-id pub-id-type="doi">10.5812/hepatmon.10640</pub-id><pub-id pub-id-type="pmid">24348633</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>SP</given-names></name><name><surname>Nigam</surname><given-names>P</given-names></name><name><surname>Misra</surname><given-names>A</given-names></name><name><surname>Guleria</surname><given-names>R</given-names></name><name><surname>Pandey</surname><given-names>RM</given-names></name><name><surname>Pasha</surname><given-names>MQ</given-names></name></person-group><article-title>Genetic variation in the patatin-like phospholipase domain-containing protein-3 (PNPLA-3) gene in Asian Indians with nonalcoholic fatty liver disease</article-title><source>Metab Syndr Relat Disord.</source><year>2013</year><volume>11</volume><issue>5</issue><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1089/met.2012.0064</pub-id><pub-id pub-id-type="pmid">23734760</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y-C</given-names></name><name><surname>Chang</surname><given-names>P-F</given-names></name><name><surname>Hu</surname><given-names>F-C</given-names></name><name><surname>Yang</surname><given-names>W-S</given-names></name><name><surname>Chang</surname><given-names>M-H</given-names></name><name><surname>Ni</surname><given-names>Y-H</given-names></name></person-group><article-title>A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children</article-title><source>J Pediatr.</source><year>2011</year><volume>158</volume><issue>5</issue><fpage>740</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2010.11.016</pub-id><pub-id pub-id-type="pmid">21168155</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Yoneda</surname><given-names>M</given-names></name><name><surname>Hyogo</surname><given-names>H</given-names></name><name><surname>Ochi</surname><given-names>H</given-names></name><name><surname>Mizusawa</surname><given-names>S</given-names></name><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Chayama</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>A</given-names></name><name><surname>Nakao</surname><given-names>K</given-names></name><name><surname>Sekine</surname><given-names>A</given-names></name></person-group><article-title>Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease</article-title><source>BMC Med Genet</source><year>2010</year><volume>11</volume><issue>1</issue><fpage>172</fpage><pub-id pub-id-type="doi">10.1186/1471-2350-11-172</pub-id><pub-id pub-id-type="pmid">21176169</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petta</surname><given-names>S</given-names></name><name><surname>Miele</surname><given-names>L</given-names></name><name><surname>Bugianesi</surname><given-names>E</given-names></name><name><surname>Camm&#x000e0;</surname><given-names>C</given-names></name><name><surname>Rosso</surname><given-names>C</given-names></name><name><surname>Boccia</surname><given-names>S</given-names></name><name><surname>Cabibi</surname><given-names>D</given-names></name><name><surname>Di Marco</surname><given-names>V</given-names></name><name><surname>Grimaudo</surname><given-names>S</given-names></name><name><surname>Grieco</surname><given-names>A</given-names></name></person-group><article-title>Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>2</issue><fpage>e87523</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0087523</pub-id><pub-id pub-id-type="pmid">24498332</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>GH</given-names></name><name><surname>Chan</surname><given-names>HY</given-names></name><name><surname>Chan</surname><given-names>HY</given-names></name><name><surname>Yeung</surname><given-names>DW</given-names></name><name><surname>Chan</surname><given-names>RM</given-names></name><name><surname>Chim</surname><given-names>AL</given-names></name><name><surname>Chan</surname><given-names>AH</given-names></name><name><surname>Choi</surname><given-names>PL</given-names></name><name><surname>Woo</surname><given-names>J</given-names></name></person-group><article-title>PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome</article-title><source>Aliment Pharmacol Ther</source><year>2014</year><volume>39</volume><issue>5</issue><fpage>532</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1111/apt.12609</pub-id><pub-id pub-id-type="pmid">24417250</pub-id></element-citation></ref></ref-list></back></article>